Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
13.07
+0.89 (7.31%)
At close: Feb 6, 2026, 4:00 PM EST
13.02
-0.05 (-0.38%)
After-hours: Feb 6, 2026, 7:50 PM EST
Janux Therapeutics Employees
Janux Therapeutics had 109 employees as of September 30, 2025. The number of employees increased by 33 or 43.42% compared to the same quarter last year.
Employees
109
Change
33
Growth
43.42%
Revenue / Employee
$91,743
Profits / Employee
-$934,817
Market Cap
786.13M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 109 | 33 | 43.42% |
| Jun 30, 2025 | 103 | 34 | 49.28% |
| Mar 31, 2025 | 91 | 23 | 33.82% |
| Dec 31, 2024 | 81 | 17 | 26.56% |
| Sep 30, 2024 | 76 | 12 | 18.75% |
| Jun 30, 2024 | 69 | 2 | 2.99% |
| Mar 31, 2024 | 68 | 6 | 9.68% |
| Dec 31, 2023 | 64 | 4 | 6.67% |
| Sep 30, 2023 | 64 | 8 | 14.29% |
| Jun 30, 2023 | 67 | 18 | 36.73% |
| Mar 31, 2023 | 62 | 21 | 51.22% |
| Dec 31, 2022 | 60 | 27 | 81.82% |
| Sep 30, 2022 | 56 | 28 | 100.00% |
| Jun 30, 2022 | 49 | 27 | 122.73% |
| Mar 31, 2022 | 41 | 25 | 156.25% |
| Dec 31, 2021 | 33 | 21 | 175.00% |
| Sep 30, 2021 | 28 | 16 | 133.33% |
| Jun 30, 2021 | 22 | - | - |
| Mar 31, 2021 | 16 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 837 |
| Valneva SE | 700 |
| Maravai LifeSciences Holdings | 550 |
| KalVista Pharmaceuticals | 270 |
| Xencor | 250 |
| Omeros | 202 |
| Nektar Therapeutics | 61 |
| Bright Minds Biosciences | 26 |
JANX News
- 12 days ago - Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer - Business Wire
- 16 days ago - Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga
- 16 days ago - Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - Reuters
- 16 days ago - Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors - Business Wire
- 6 weeks ago - Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - Business Wire
- 2 months ago - Janux Therapeutics Stock Hits 52-Week Low After Trial Update - Benzinga
- 2 months ago - Janux dives as gaps in prostate cancer study data worry investors - Reuters
- 2 months ago - Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga